Voyxact in Lebanon

Voyxact - overview

Voyxact (sibeprenlimab-szsi) is manufactured by Otsuka and indicated for Proteinuria reduction in primary IgA nephropathy (IgAN) at risk of progression. It is an oral small molecule approved by the US FDA in 2025 and may be accessible to patients in Lebanon through a Named Patient Program or personal-import pathway.

Access in Lebanon

Lebanon's MoPH has a functional (if under-resourced) named-patient pathway for unregistered drugs.

How Reserve Meds coordinates access in Lebanon

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Lebanon-specific eligibility.
3. Treating physician in Lebanon issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Voyxact from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Lebanon.

Typical timeline for Lebanon

End-to-end, most requests are completed in 2-6 weeks. Lebanon's tier 3 regulatory maturity typically supports longer processing times.

What patients and physicians in Lebanon ask

• Is the pathway legal in Lebanon? Yes - it operates under Lebanon's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Lebanon able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Voyxact in Lebanon

Join the Voyxact waitlist